ADMA Biologics (ADMA) Stock Price, News & Analysis

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 1-year target prices for ADMA Biologics' shares. Their ADMA share price targets range from $6.00 to $10.00. On average, they anticipate the company's share price to reach $7.88 in the next year. This suggests a possible upside of 27.0% from the stock's current price.
View analysts price targets for ADMA or view top-rated stocks among Wall Street analysts.

ADMA Biologics' stock was trading at $4.52 at the beginning of 2024. Since then, ADMA stock has increased by 37.2% and is now trading at $6.20.
View the best growth stocks for 2024 here.

ADMA Biologics saw a drop in short interest in March. As of March 31st, there was short interest totaling 7,290,000 shares, a drop of 8.8% from the March 15th total of 7,990,000 shares. Based on an average daily volume of 2,750,000 shares, the short-interest ratio is presently 2.7 days.
View ADMA Biologics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ADMA earnings forecast.

ADMA Biologics, Inc. (NASDAQ:ADMA) announced its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. The biotechnology company earned $73.90 million during the quarter, compared to analyst estimates of $73.50 million. ADMA Biologics had a positive trailing twelve-month return on equity of 0.49% and a negative net margin of 10.94%.

ETFs with the largest weight of ADMA Biologics (NASDAQ:ADMA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).iShares Micro-Cap ETF (IWC).

ADMA Biologics issued an update on its FY 2025 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $380.0 million-.

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

ADMA Biologics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.11%), First Hawaiian Bank (0.05%), EWG Elevate Inc. (0.04%), Prism Advisors Inc. (0.01%) and Viewpoint Capital Management LLC (0.01%). Insiders that own company stock include Adam S Grossman, Brian Lenz, Bryant Fong, Jerrold B Grossman, Perceptive Advisors Llc, Steve Elms and Young Kwon.
View institutional ownership trends.

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.